Hims & Hers Health (NYSE:HIMS) Given New $20.00 Price Target at TD Cowen

Hims & Hers Health (NYSE:HIMS) had its target price reduced by equities researchers at TD Cowen from $30.00 to $20.00 in a report released on Monday,Benzinga reports. The brokerage presently has a “hold” rating on the stock. TD Cowen’s price objective points to a potential upside of 14.13% from the stock’s current price.

A number of other research analysts also recently issued reports on HIMS. Evercore started coverage on Hims & Hers Health in a research note on Monday, January 12th. They issued an “in-line” rating and a $33.00 price objective for the company. Zacks Research cut Hims & Hers Health from a “hold” rating to a “strong sell” rating in a research report on Monday, January 19th. Barclays began coverage on shares of Hims & Hers Health in a research note on Monday, December 8th. They issued an “overweight” rating and a $48.00 target price for the company. Citigroup decreased their target price on shares of Hims & Hers Health from $30.00 to $16.50 and set a “sell” rating on the stock in a report on Monday. Finally, Bank of America cut their price target on shares of Hims & Hers Health from $26.00 to $21.00 and set an “underperform” rating for the company in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have given a Hold rating and four have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $39.96.

Hims & Hers Health Stock Down 23.9%

Shares of NYSE:HIMS traded down $5.50 during mid-day trading on Monday, hitting $17.52. 74,476,137 shares of the company traded hands, compared to its average volume of 22,738,471. Hims & Hers Health has a 12-month low of $16.35 and a 12-month high of $72.98. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. The stock has a market cap of $3.99 billion, a P/E ratio of 32.43, a P/E/G ratio of 3.79 and a beta of 2.43. The stock has a 50-day moving average price of $32.96 and a two-hundred day moving average price of $43.32.

Hims & Hers Health announced that its Board of Directors has initiated a stock repurchase plan on Monday, November 17th that allows the company to buyback $250.00 million in shares. This buyback authorization allows the company to purchase up to 3% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s management believes its stock is undervalued.

Insiders Place Their Bets

In other news, insider Patrick Harrison Carroll sold 10,021 shares of Hims & Hers Health stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $367,870.91. Following the sale, the insider directly owned 169,940 shares of the company’s stock, valued at approximately $6,238,497.40. The trade was a 5.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Irene Becklund sold 8,411 shares of the business’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $308,767.81. Following the completion of the sale, the insider owned 2,126 shares in the company, valued at approximately $78,045.46. This trade represents a 79.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 129,337 shares of company stock valued at $4,651,648. 13.71% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Hims & Hers Health

Large investors have recently bought and sold shares of the business. Virtus Advisers LLC acquired a new stake in Hims & Hers Health during the 2nd quarter valued at approximately $26,000. Quent Capital LLC acquired a new stake in shares of Hims & Hers Health during the 3rd quarter worth approximately $28,000. Flagship Harbor Advisors LLC purchased a new position in Hims & Hers Health in the fourth quarter valued at $28,000. Binnacle Investments Inc purchased a new position in shares of Hims & Hers Health in the 3rd quarter valued at about $28,000. Finally, Quaker Wealth Management LLC acquired a new position in Hims & Hers Health in the 2nd quarter worth about $29,000. Institutional investors own 63.52% of the company’s stock.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Neutral Sentiment: Bank of America trimmed its price target to $21 and kept an “underperform” view — the PT implies some upside from current levels but reflects weak near-term confidence. Bank of America price target
• Neutral Sentiment: HIMS has been a trending / widely watched stock, drawing additional short-term volatility from high retail and media attention. (Coverage: Zacks, MarketWatch commentary). Zacks: trending stock
• Neutral Sentiment: Trading showed extreme volume relative to average (large block trading), underscoring forced or broad-based selling pressure rather than isolated news impact.
• Negative Sentiment: Novo Nordisk filed a patent-infringement lawsuit against Hims over compounded semaglutide products and is asking for a permanent ban and damages — this escalates legal risk and threatens any future GLP‑1-related revenue. Reuters: Novo Nordisk sues Hims & Hers
• Negative Sentiment: Hims & Hers quickly stopped offering its low-cost compounded semaglutide (Wegovy knockoff) after FDA scrutiny and industry backlash — the pullback removes a nascent product that had been presented as a growth driver and signals regulatory vulnerability. ProactiveInvestors: Hims & Hers scraps low-cost weight-loss pill
• Negative Sentiment: Multiple outlets note the company faces heightened regulatory and reputational risk (Barron’s, CNBC, AP) and that the GLP‑1 move has backfired, pressuring near-term revenue and raising questions about execution/management. CNBC: Novo Nordisk sues Hims & Hers
• Negative Sentiment: Citigroup cut its price target sharply to $16.50 and moved to a “sell” rating — an explicit analyst signal that downside is expected until legal/regulatory clarity and growth drivers stabilize. Benzinga: Citigroup lowers target
• Negative Sentiment: Analyst and commentary pieces (Seeking Alpha, Forbes, Barron’s) highlight decelerating growth, reliance on GLP‑1 initiatives that are now uncertain, and management risk — factors that increase perceived downside risk for investors. Seeking Alpha: critical analysis

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.